Abstract Library

#4637 Non-functional retroperitoneal paraganglioma in a young patient: A case report

Introduction: Paragangliomas are neuroendocrine tumours arising in the parasympathetic nervous system, outside the adrenal gland. Retroperitoneal location is extremely rare. Non-functional paragangliomas often represent a diagnostic challenge.

Conference:

Presenting Author:

Authors: Aris H, Saidi M, Lahfa I,

Keywords: retroperitoneal paraganglioma, surgery, monitoring,

#4251 Upfront Oxaliplatin–Fluoropyrimidine chemotherapy and Somatostatin Analogues (SSA) in advanced well-differentiated G2/G3 gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are frequently diagnosed at advanced stage. For well-differentiated somatostatin receptor-positive (SSTR +) NETs, somatostatin analogues (SSAs) are the preferred first-line therapy. However, in patients (pts) with G2/G3 and a high tumor burden, SSA alone might not be enough.

Conference:

Presenting Author:

Authors: Maratta M, Sparagna I, d'Agostino F, Occhipinti D, Raia S,

Keywords: gastroenteropancreatic NET, neuroendocrine tumor, chemotherapy, conversion surgery, neoadjuvant treatment,

#3882 Adjuvant therapy for pancreatic neuroendocrine tumors – Expert consensus and recommendations for future research

Introduction: With the increase of incidentally diagnosed pancreatic neuroendocrine tumors (panNEN), more patients are treated with curative intent. Survival in patients with a panNEN is impacted by the development of recurrence, but postoperative adjuvant therapy is not yet recommended in guidelines due to absence of evidence. Multiple clinicopathological characteristics have been described in literature to identify patients at high-risk of recurrence who might benefit from adjuvant treatment. Since panNEN are rare tumors, prospective randomized controlled studies on the role of adjuvant therapy in these patients have not been performed.

Conference:

Presenting Author: Heidsma C

Authors: Heidsma C, Engelsman A, Klümpen H, Falconi M, Frilling A,

Keywords: pancreatic neuroendocrine tumor, recurrence, adjuvant therapy, prevention, expert consensus, future research,

#3880 Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90-Yttrium versus 177-Lutetium – Comparison of clinico-pathological and survival outcomes

Introduction: The role of peptide receptor radionuclide therapy (PRRT) as neoadjuvant treatment in patients with is still controversial, although recent experiences showed encouraging results in terms of oncological outcomes.

Conference:

Presenting Author: Genova L

Authors: Genova L, Andreasi V, Partelli S, Muffatti F, Battistella A,

Keywords: peptide receptor radionuclide therapy, prrt, neoadjuvant, surgery, yttrium, lutetium,

#3851 68Ga-DOTATOC PET radiomics as a novel preoperative predictive tool for PanNETs aggressiveness

Introduction: The knowledge of Pancreatic Neuroendocrine Tumors (PanNETs) features of aggressiveness before surgery is fundamental for an appropriate treatment planning.

Conference:

Presenting Author:

Authors: Mapelli P, Bezzi C, Ghezzo S, Muffatti F, Andreasi V,

Keywords: 68Ga-DOTATOC, NET, PET, radiomics,